Therapeutic Asset Ratings
138 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Inqovi
Myelodysplastic Syndromes
National Cancer Institute (NCI)
P1/2
CC
(45)
Rivogenlecleucel
Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
P2/3
CC
(44)
Abd-3001
Myelodysplastic Syndromes
Advanced BioDesign
P1/2
CC
(41)
Bexmarilimab
Myelodysplastic Syndromes
Faron Pharmaceuticals Ltd
P1/2
CC
(41)
Ctx-712
Myelodysplastic Syndromes
Chordia Therapeutics, Inc.
P1/2
CC
(41)
Dordaviprone
Myelodysplastic Syndromes
University of Nebraska
P1/2
CC
(41)
Enzomenib
Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
P1/2
CC
(41)
Equine Atg
Myelodysplastic Syndromes
Instituto Nacional de Cancer, Brazil
P1/2
CC
(41)
Ex-Vivo Expanded Γδ T Cell Infusion
Myelodysplastic Syndromes
Chinese PLA General Hospital
P1/2
CC
(41)
imm01
Myelodysplastic Syndromes
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
P1/2
CC
(41)
Mobinitinib
Myelodysplastic Syndromes
Ellipses Pharma
P1/2
CC
(41)
rp7214
Myelodysplastic Syndromes
Rhizen Pharmaceuticals SA
P1/2
CC
(41)
sar443579
Myelodysplastic Syndromes
Sanofi
P1/2
CC
(41)
Sonrotoclax
Myelodysplastic Syndromes
BeiGene
P1/2
CC
(41)
Tgrx-814
Myelodysplastic Syndromes
Shenzhen TargetRx Co., Ltd.
P1/2
CC
(41)
tqb3454
Myelodysplastic Syndromes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
P1/2
CC
(41)
vor33
Myelodysplastic Syndromes
Vor Biopharma
P1/2
CC
(41)
Zilurgisertib
Myelodysplastic Syndromes
Incyte Corporation
P1/2
CC
(41)
Γδ T Cells
Myelodysplastic Syndromes
Chinese PLA General Hospital
P1/2
CC
(41)
Donor T Cells
Myelodysplastic Syndromes
Dana-Farber Cancer Institute
P2
CC
(40)
Jnj-64619178
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
CC
(40)
Jnj-74856665
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
CC
(40)
PRT1419
Myelodysplastic Syndromes
Prelude Therapeutics
P1
C
(39)
Vic-1911
Myelodysplastic Syndromes
Masonic Cancer Center, University of Minnesota
P1/2
C
(39)
Anzurstobart
Myelodysplastic Syndromes
Bristol-Myers Squibb
P1
C
(37)
Showing 76 to 100 of 138 assets
Previous
Page 4 of 6
Next
